Kristi Moriarity
Nurse Practitioner · Racine, WINPI 1447642202
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 25.9% of the total. 2025 is the largest year on record at $3,031, more than ten times the $14 reported in 2021. Among nurse practitioner clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$771
- Lundbeck LLC$686
- AbbVie$625
- Alkermes, Inc.$563
- Johnson & Johnson$516
- plus $2K from 8 others
What the payments were for
- Food & beverage$6,36597%
- Education$2153%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 88 | $1,703 |
| Neurocrine Biosciences, Inc. | 36 | $771 |
| Lundbeck LLC | 38 | $686 |
| AbbVie | 42 | $625 |
| Alkermes, Inc. | 25 | $563 |
| Johnson & Johnson | 27 | $516 |
| Otsuka America Pharmaceutical, Inc. | 35 | $449 |
| Axsome Therapeutics, Inc. | 17 | $425 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $304 |
| Vanda Pharmaceuticals Inc. | 9 | $225 |
| Indivior Inc. | 7 | $134 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| Noven Therapeutics, LLC | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
$6,580 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 118 | $965,398 |
| Invega SustennaPaliperidone Palmitate | 180 | $619,789 |
| AustedoDeutetrabenazine | 36 | $356,421 |
| VraylarCariprazine Hcl | 182 | $252,811 |
| Abilify MaintenaAripiprazole | 70 | $198,085 |
| Abilify AsimtufiiAripiprazole | 25 | $149,141 |
| Austedo XrDeutetrabenazine | 19 | $105,821 |
| Invega TrinzaPaliperidone Palmitate | 11 | $91,980 |
| LybalviOlanzapine/Samidorphan Malate | 48 | $75,118 |
| RexultiBrexpiprazole | 40 | $61,999 |
| BelsomraSuvorexant | 110 | $50,674 |
| FanaptIloperidone | 37 | $47,254 |
| TrintellixVortioxetine Hydrobromide | 89 | $42,984 |
| AristadaAripiprazole Lauroxil | 13 | $41,458 |
| UzedyRisperidone | 17 | $39,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $771 | $965,398118 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $516 | $711,769191 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $1,703 | $501,94472 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $449 | $409,225135 claims |
| AbbVieVraylar | $625 | $252,811182 claims |
| Alkermes, Inc.Lybalvi, Aristada | $563 | $116,57661 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $225 | $47,25437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Other nurse practitioner in Racine
- Jodi StrongStevens Point$246K
- Jo Ellen FrawleyPrairie du Sac$194K
- Trisha WilcoxMilwaukee$174K
- Sally BowaGreen Bay$117K
- Christina SauldMilwaukee$111K
- Melissa WendellWausau$98K
- Nicole BarteltWaukesha$85K
- Kari FisherPrairie du Sac$57K
- Roxanne RadichAppleton$54K
- Kelly FlugaurMilwaukee$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.